Moxifloxacin - Revision history

Danbot: Restore original dosing content alongside dynamic SMW tables

2026-03-20T02:38:29Z

Restore original dosing content alongside dynamic SMW tables

← Older revision		Revision as of 02:38, 20 March 2026
Line 5:		Line 5:

	==Adult Dosing==		==Adult Dosing==
			*400mg PO/IV daily


	===Indications by Disease===		===Indications by Disease===
	{{#ask: [[Has DrugName::Moxifloxacin]] [[Has Population::Adult]]		{{#ask: [[Has DrugName::Moxifloxacin]] [[Has Population::Adult]]
	\|?Treats disease=Disease		\|?Treats disease=Disease
	\|?Has Dose=Dose		\|?Has Dose=Dose
	\|?Has Context=Context		\|?Has Context=Context
	\|format=table		\|format=table
	\|limit=50		\|limit=50
	\|mainlabel=-		\|mainlabel=-
	\|headers=show		\|headers=show
	\|sort=Treats disease		\|sort=Treats disease
	}}		}}

	==Pediatric Dosing==		==Pediatric Dosing==
			''Safety/efficacy not established''


	===Indications by Disease===		===Indications by Disease===
	{{#ask: [[Has DrugName::Moxifloxacin]] [[Has Population::Pediatric]]		{{#ask: [[Has DrugName::Moxifloxacin]] [[Has Population::Pediatric]]
	\|?Treats disease=Disease		\|?Treats disease=Disease
	\|?Has Dose=Dose		\|?Has Dose=Dose
	\|?Has Context=Context		\|?Has Context=Context
	\|format=table		\|format=table
	\|limit=50		\|limit=50
	\|mainlabel=-		\|mainlabel=-
	\|headers=show		\|headers=show
	\|sort=Treats disease		\|sort=Treats disease
	}}		}}

2026-03-20T01:52:20Z

Replace manual dosing with dynamic SMW tables (Adult + Pediatric)

@@ Line 5: / Line 5: @@
 ==Adult Dosing==
-*400mg PO/IV daily
+===Indications by Disease===
 ==Pediatric Dosing==
-''Safety/efficacy not established''
+===Indications by Disease===
 ==Special Populations==

2025-07-18T17:06:40Z

← Older revision		Revision as of 17:06, 18 July 2025
Line 1:		Line 1:
	==General==		==General==
	*Type:[[Is Generation:: 4th ~~Generation~~]] [[Is DrugClass::Fluoroquinolones]]		*Type:[[Is Generation:: 4th generation]] [[Is DrugClass::Fluoroquinolones]]
	*Dosage Forms:		*Dosage Forms:
	*Common Trade Names: Avelox		*Common Trade Names: Avelox

2025-07-18T17:04:40Z

← Older revision		Revision as of 17:04, 18 July 2025
Line 1:		Line 1:
	==General==		==General==
	*Type:[[Is DrugClass::Fluoroquinolones]]		*Type:[[Is Generation:: 4th Generation]] [[Is DrugClass::Fluoroquinolones]]
	*Dosage Forms:		*Dosage Forms:
	*Common Trade Names: Avelox		*Common Trade Names: Avelox

2025-07-18T17:00:24Z

← Older revision		Revision as of 17:00, 18 July 2025
Line 1:		Line 1:
	==General==		==General==
	*Type: [[~~Fluoroquinolone~~]]		*Type:[[Is DrugClass::Fluoroquinolones]]
	*Dosage Forms:		*Dosage Forms:
	*Common Trade Names: Avelox		*Common Trade Names: Avelox

2020-03-23T19:21:30Z

Adverse Reactions

← Older revision		Revision as of 19:21, 23 March 2020
Line 25:		Line 25:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
			*QT prolongation <ref>Hooper DC. Fluoroquinolones. In: UpToDate. Waltham, MA. www.uptodate.com. Accessed March 23, 2020.</ref>
			**Amongst fluoroquinolones, the risk of arrhythmia is highest with moxifloxacin

	===Common===		===Common===
			*GI
			**Gastritis <ref>Hooper DC. Fluoroquinolones. In: UpToDate. Waltham, MA. www.uptodate.com. Accessed March 23, 2020.</ref>
			**C. difficile associated disease <ref>Hooper DC. Fluoroquinolones. In: UpToDate. Waltham, MA. www.uptodate.com. Accessed March 23, 2020.</ref>

	==Pharmacology==		==Pharmacology==

2020-03-23T19:13:03Z

Antibiotic SensitivitiesSanford Guide to Antimicrobial Therapy 2014

← Older revision		Revision as of 19:13, 23 March 2020
Line 36:		Line 36:
	==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==		==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
	*In general, less activity against pseudomonas than [[ciprofloxacin]], but has more activity against MSSA<ref>Culley C et al. Moxifloxacin: Clinical Efficacy and Safety. Am J Health Syst Pharm. 2001;58(5). http://www.medscape.com/viewarticle/406946_3</ref>		*In general, less activity against pseudomonas than [[ciprofloxacin]], but has more activity against MSSA<ref>Culley C et al. Moxifloxacin: Clinical Efficacy and Safety. Am J Health Syst Pharm. 2001;58(5). http://www.medscape.com/viewarticle/406946_3</ref>
			*Compared to levofloxacin, moxifloxacin has greater in vitro activity against strep pneumoniae, staph aureus and some enterococcus strains <ref>Oliphant CM, Green G. Quinolones: A Comprehensive Review. American Family Physician. https://www.aafp.org/afp/2002/0201/p455.html. Published February 1, 2002. Accessed March 23, 2020.</ref>

	{\| class="wikitable"		{\| class="wikitable"

2019-09-22T23:43:01Z

← Older revision		Revision as of 23:43, 22 September 2019
Line 1:		Line 1:
	==General==		==General==
	*Type:		*Type: [[Fluoroquinolone]]
	*Dosage Forms:		*Dosage Forms:
	*Common Trade Names: Avelox		*Common Trade Names: Avelox

	==Adult Dosing==		==Adult Dosing==
			*400mg PO/IV daily

	==Pediatric Dosing==		==Pediatric Dosing==
			''Safety/efficacy not established''

	==Special Populations==		==Special Populations==
	*Pregnancy:		*Pregnancy: C
	*Lactation:		*Lactation: Unknown
	*Renal Dosing		*Renal Dosing
	**Adult		**Adult
Line 162:		Line 164:
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:ID]]

2017-08-30T23:22:57Z

2016-03-22T15:53:47Z

Text replacement - "Category:Drugs" to "Category:Pharmacology"